These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16897607)

  • 1. Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study.
    Tai YF; Ahsan RL; de Yébenes JG; Pavese N; Brooks DJ; Piccini P
    J Neural Transm (Vienna); 2007 Mar; 114(3):337-40. PubMed ID: 16897607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography.
    Piccini P; de Yebenez J; Lees AJ; Ceravolo R; Turjanski N; Pramstaller P; Brooks DJ
    Arch Neurol; 2001 Nov; 58(11):1846-51. PubMed ID: 11708994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography in progressive supranuclear palsy.
    Bhatt MH; Snow BJ; Martin WR; Peppard R; Calne DB
    Arch Neurol; 1991 Apr; 48(4):389-91. PubMed ID: 1901484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
    Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased basal ganglia binding of
    Smith R; Schain M; Nilsson C; Strandberg O; Olsson T; Hägerström D; Jögi J; Borroni E; Schöll M; Honer M; Hansson O
    Mov Disord; 2017 Jan; 32(1):108-114. PubMed ID: 27709757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
    Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
    Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.
    Burn DJ; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigrofrontal dopaminergic function as assessed by 18F-dopa PET.
    Otsuka M; Ichiya Y; Kuwabara Y; Sasaki M; Yoshida T; Fukumura T; Masuda K
    Nucl Med Commun; 1995 Dec; 16(12):1021-5. PubMed ID: 8719983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography in degenerative disorders of the dopaminergic system.
    Karbe H; Holthoff V; Huber M; Herholz K; Wienhard K; Wagner R; Heiss WD
    J Neural Transm Park Dis Dement Sect; 1992; 4(2):121-30. PubMed ID: 1571076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parametric imaging of the rate constant Ki using [18Fluoro]-L-dopa positron emission tomography in progressive supranuclear palsy.
    Cordes M; Snow BJ; Morrison S; Sossi V; Ruth TJ; Calne DB
    Neuroradiology; 1993; 35(6):404-9. PubMed ID: 8377907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
    Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
    Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography (PET) in "pure akinesia".
    Taniwaki T; Hosokawa S; Goto I; Fujii N; Otsuka M; Kuwabara Y; Ichiya Y; Hasuo K; Kato M
    J Neurol Sci; 1992 Jan; 107(1):34-9. PubMed ID: 1578232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcortical
    Cho H; Choi JY; Hwang MS; Lee SH; Ryu YH; Lee MS; Lyoo CH
    Mov Disord; 2017 Jan; 32(1):134-140. PubMed ID: 27813160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated striatal dopamine function linked to prodromal signs of schizophrenia.
    Howes OD; Montgomery AJ; Asselin MC; Murray RM; Valli I; Tabraham P; Bramon-Bosch E; Valmaggia L; Johns L; Broome M; McGuire PK; Grasby PM
    Arch Gen Psychiatry; 2009 Jan; 66(1):13-20. PubMed ID: 19124684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.